Available option
Cagrilintide 2.5mg + Semaglutide 2.5mg
Lyophilised powder
- Strength
- Cagrilintide 2.5mg + Semaglutide 2.5mg
- Format
- Lyophilised powder
Bear Biotech catalogue
CagriSema
Combined amylin and GLP-1 receptor research materials
- Amylin signalling
- GLP-1 signalling
- Combination research
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is CagriSema?
CagriSema is an investigational combination research concept pairing the long-acting amylin analogue cagrilintide with semaglutide-mediated GLP-1 signalling. Research interest centres on whether two complementary appetite and metabolic pathways provide effects that differ from GLP-1 signalling alone. Evidence comes from controlled human development programmes, not from generic research material.
Published phase 2 and phase 3 human studies; investigational combination
Research focus
Key research areas
CagriSema research: combining amylin and GLP-1 pathways
CagriSema describes coadministration of cagrilintide and semaglutide rather than a single molecular entity. Controlled studies concern defined component formulations and study protocols. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- Amylin signalling
- GLP-1 signalling
- Combination research
Representative primary research
Representative research
A randomised phase-2 trial studied co-administered regulated cagrilintide and semaglutide products.
- Co-administered cagrilintide with semaglutide in type 2 diabetes: a phase 2 trial ↗ The study used 2.4mg pharmaceutical components, not the catalogue 2.5mg + 2.5mg lyophilised formulation.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- CagriSema
- Research category
- Combined amylin and GLP-1 receptor research materials
- Evidence position
- Published phase 2 and phase 3 human studies; investigational combination
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
Why are amylin and GLP-1 signalling studied together in CagriSema?
CagriSema research combines amylin and GLP-1 signalling in one investigational regimen. Researchers examine how the two component pathways contribute to metabolic endpoints.
Why must the cagrilintide and semaglutide components remain explicitly identified?
Combination studies must preserve the identity and proportion of cagrilintide and semaglutide rather than treating CagriSema as a single interchangeable material.
What do investigational CagriSema trials not prove about a generic combined material?
Published phase 2 and phase 3 studies concern defined investigational formulations. They do not establish equivalence for a generic combined research material.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.